PEDIATRICS Vol. 95 No. 2 February 1995, pp. 320
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gadomski, A.
Right arrow Articles by Keane, V.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gadomski, A.
Right arrow Articles by Keane, V.

Letters to the Editor

Anne Gadomski MD, MPH1, Richard Lichenstein MD2, James King MD2, and Virginia Keane MD2

1 The Mary Imogene Bassett Hospital, Cooperstown, NY
2 University of Maryland, Baltimore, MD

We appreciate Dr Serwint's careful reading of our study and respond to the three points she raises as follows.

Outcomes were measured at 30 and 60 minutes after treatment because clinical responses to nebulized albuterol, as well as side effects and oxygen desaturation, among infants and children have been reported sooner than 1 hour posttreatment in several studies (citations limited to recent references).1-4 It is also common clinical practice to assess children receiving nebulized albuterol every 20 to 30 minutes.